Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences is poised for strong long-term growth as their ABC platform has shown robust results in both their investigational medicines, tarcocimab and KSI-501. The successful GLOW2 trial in DR validates the reformulated design and supports its potential for addressing current anti-VEGF limitations. With multiple pivotal data readouts expected in 2026 and 2027, Kodiak Sciences has the potential to become a leader in the treatment of retinal diseases.

Bears say

Kodiak Sciences is a high-risk investment due to their reliance on the success of their investigational medicines, especially tarcocimab, which is expected to face competition from other anti-VEGF therapies. Additionally, the company may need to raise additional capital before achieving profitability, potentially resulting in share dilution for shareholders. Furthermore, there are potential clinical and regulatory risks associated with the development and approval of their pipeline products, which could lead to delays or failure. Risks aside, Kodiak's financial data suggests a reliance on external funding sources until at least 2027, which could impact their financial health and negatively affect their valuation.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of Jun 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.